Sumitomo Chemical and Sumitomo Pharmaceutical (tickers: 4005, 4506): The ¥116 billion Swiss Shuffle
GOTHAM CITY RESEARCH’S OPINIONS
Sumi Pharma’s FY2025 financial statements are misstated by 116-165 billion. Financial statements will be restated and the Company will face an investigation.
Pharma manipulates receivables to fuel Pharma and Chemical’s profits. Without these, earnings collapse, and Chemical’s FY2025 Leverage is closer to 10x rather than 3x.
Shares of both Chemical and Pharma are uninvestable, and face 50%-100% downside risk.
SUMMARY OF THE BASES OF OPINIONS
Sumitomo Pharma FY2025 earnings account for 92% of Sumitomo Chemical FY2025 earnings.
Chemical’s FY2025 earnings are inflated by non-recurring sources. Removing these, reduces its earnings 84%-111%.
Pharma FY2025 earnings are inflated by non-recurring sources. Removing these reduces earnings by ~50%.
Pharma FY2025 earnings are inflated by anomalous accounts receivable growth. Removing these, reduces earnings by an additional 50%.
Pharma’s FY2025 Receivables grew 76% YoY while revenue grew 14%. We suspect channel stuffing, aggressive revenue recognition, or fictitious revenue.
A March press release announced a 48 billion dividend to Pharma from its Switzerland subsidiary SMPS, weeks before Pharma’s 116.4 billion JPY public offering in April.
Yet SMPS paid Pharma’s parent company a 164 billion dividend, not 48 billion, according to the notes to the Pharma’s parent company 2025FY financial statements.
The 164 billion dividend does not appear on the income statement, even though it is explicitly described as an income statement activity within the 2025FY period.
The 164 billion dividend is a distribution in-kind, in the form of accounts receivables previously held by SMPS.
The 116 billion difference between the two differing dividend figures is not explained. We are unable to reconcile this difference to any accounts found within the FY 2025 Pharma financial statements.
The 48 billion dividend represents ~42% of the parent company’s net income. The 164 billion amount represents 143%, implying the parent company is loss making.
Although Pharma and Chemical share the same auditor, KPMG AZSA, the Swiss subsidiary’s auditor is KPMG. They are separate legal entities.
for the full report please download here:
I really appreciated your deep dive into the financial intricacies of Sumitomo Chemical and Pharmaceutical! Having worked in biotech investing, cookie clicker I've seen how corporate restructuring can dramatically alter market positions. The Swiss shuffle concept is fascinating—excited to see how these moves will play out!
Lần đầu biết đến v799n.com, mình bắt gặp cái tên này khá nhiều trong những bài thảo luận về nền tảng giải trí trực tuyến. Từ sự tò mò, mình đã truy cập thử để xem cách website vận hành cũng như quan sát phần giao diện bên ngoài. Cảm nhận đầu tiên là trang được thiết kế theo hướng khá tối giản, các khu vực chính được sắp xếp tương đối dễ nhìn và màu sắc không gây cảm giác quá chói. Quá trình thao tác cũng khá ổn, thời gian tải trang tương đối nhanh và việc chuyển đổi giữa các mục diễn ra khá mượt. Dù vậy, mình vẫn giữ thái độ thận trọng vì chưa có…
The detail that the 164 billion dividend was paid in kind — as receivables held by SMPS rather than cash — is the piece that stuck with me, since it explains how a figure described as income statement activity ends up traceable only through the notes rather than the income statement itself. On a separate and unrelated note, The Voicer Choicer The Voicer Choicer is a browser-based voice game.
The scale of these accounting discrepancies and the complex web of Swiss dividends uncovered here is truly staggering. Analyzing such massive financial structures demands robust systems and meticulous technical planning to catch hidden anomalies. Companies aiming to build secure, high-integrity digital infrastructures often rely on specialized expertise, such as AI Product Development Services, to ensure every layer functions transparently. Brilliant and eye-opening forensic research report.
This forensic financial breakdown of Sumitomo's discrepancies is exceptionally thorough, especially regarding the complex handling of receivables and dividends. Unraveling such massive corporate accounting puzzles requires deep data evaluation, much like how modern analytical tools and automated interfaces process intricate data sets. For those looking to understand how intelligent systems handle complex information flows and inquiries, exploring insights on Chatbot vs Conversational AI offers a useful technological parallel. Excellent deep dive into corporate auditing.